Respiratory Medicine
Volume 104, Issue 4 , Pages 606-611 , April 2010

Adenosine for vasoreactivity testing in pulmonary hypertension: A head-to-head comparison with inhaled nitric oxide

Received 28 July 2009 ,Accepted 17 November 2009.

References 

  1. Galie N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: the task force on diagnosis and treatment of pulmonary arterial hypertension of the European Society of Cardiology. Eur Heart J. 2004;25(24):2243–2278
  2. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med. 2004;351(16):1655–1665
  3. Ghofrani HA, Wilkins MW, Rich S. Uncertainties in the diagnosis and treatment of pulmonary arterial hypertension. Circulation. 2008;118(11):1195–1201
  4. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327(2):76–81
  5. Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111(23):3105–3111
  6. Weir EK, Rubin LJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. The acute administration of vasodilators in primary pulmonary hypertension. Experience from the national institutes of health registry on primary pulmonary hypertension. Am Rev Respir Dis. 1989;140(6):1623–1630
  7. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest. 2007;131(6):1917–1928
  8. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension. A report of the American College of Cardiology Foundation Task Force on expert consensus documents and the American Heart Association. Circulation. 2009;119:2250–2294
  9. Hoeper MM, Lee SH, Voswinckel R, Palazzini M, Jais X, Marinelli A, et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol. 2006;48(12):2546–2552
  10. Morgan JM, McCormack DG, Griffiths MJ, Morgan CJ, Barnes PJ, Evans TW. Adenosine as a vasodilator in primary pulmonary hypertension. Circulation. 1991;84(3):1145–1149
  11. Nootens M, Schrader B, Kaufmann E, Vestal R, Long W, Rich S. Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension. Chest. 1995;107(1):54–57
  12. Schrader BJ, Inbar S, Kaufmann L, Vestal RE, Rich S. Comparison of the effects of adenosine and nifedipine in pulmonary hypertension. J Am Coll Cardiol. 1992;19(5):1060–1064
  13. Berner M, Beghetti M, Spahr-Schopfer I, Oberhansli I, Friedli B. Inhaled nitric oxide to test the vasodilator capacity of the pulmonary vascular bed in children with long-standing pulmonary hypertension and congenital heart disease. Am J Cardiol. 1996;77(7):532–535
  14. Nihil MR. Clinical management of patients with pulmonary hypertension. In:  Emmanouilides GC,  Riemenschneider TA,  Allen HD,  Gutgesell HP editor. Moss and Adams heart disease in infants, children, and adolescents. Baltimore: Williams & Wilkins; 1995;p. 1695–1711
  15. Klings ES, Hill NS, Ieong MH, Simms RW, Korn JH, Farber HW. Systemic sclerosis-associated pulmonary hypertension: short- and long-term effects of epoprostenol (prostacyclin). Arthritis Rheum. 1999;42(12):2638–2645
  16. Simonneau G, Fartoukh M, Sitbon O, Humbert M, Jagot JL, Herve P. Primary pulmonary hypertension associated with the use of fenfluramine derivatives. Chest. 1998;114(Suppl. 3):195S–199S
  17. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet. 1991;338(8776):1173–1174
  18. Sitbon O, Humbert M, Jagot JL, Taravella O, Fartoukh M, Parent F, et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J. 1998;12(2):265–270
  19. Hoeper MM, Olschewski H, Ghofrani HA, Wilkens H, Winkler J, Borst MM, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group J Am Coll Cardiol. 2000;35(1):176–182
  20. Blomstrom-Lundqvist C, Scheinman MM, Aliot EM, Alpert JS, Calkins H, Camm AJ, et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias–executive summary. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society. J Am Coll Cardiol. 2003;42(8):1493–1531
  21. Tabrizchi R, Bedi S. Pharmacology of adenosine receptors in the vasculature. Pharmacol Ther. 2001;91(2):133–147
  22. Paidas CN, Dudgeon DL, Haller JA, Clemens MG. Adenosine triphosphate: a potential therapy for hypoxic pulmonary hypertension. J Pediatr Surg. 1988;23(12):1154–1160
  23. Paidas CN, Dudgeon DL, Haller JA, Clemens MG. Adenosine triphosphate (ATP) treatment of hypoxic pulmonary hypertension (HPH): comparison of dose dependence in pulmonary and renal circulations. J Surg Res. 1989;46(4):374–379
  24. Konduri GG, Garcia DC, Kazzi NJ, Shankaran S. Adenosine infusion improves oxygenation in term infants with respiratory failure. Pediatrics. 1996;97(3):295–300
  25. Fullerton DA, Jaggers J, Jones SD, Brown JM, McIntyre RC. Adenosine for refractory pulmonary hypertension. Ann Thorac Surg. 1996;62(3):874–877
  26. Fullerton DA, Kirson LE, Jones SD, McIntyre RC. Adenosine is a selective pulmonary vasodilator in cardiac surgical patients. Chest. 1996;109(1):41–46
  27. Ng C, Franklin O, Vaidya M, Pierce C, Petros A. Adenosine infusion for the management of persistent pulmonary hypertension of the newborn. Pediatr Crit Care Med. 2004;5(1):10–13
  28. Tricoci P, Allen JM, Kramer JM, Califf RM, Smith SC. Scientific evidence underlying the ACC/AHA clinical practice guidelines. J Am Med Assoc. 2009;301(8):831–841

☆ Financial support: AL Ribeiro is supported by the Brazilian research agencies CNPq – Conselho Nacional de Desenvolvimento Científico e Tecnológico, Brasília, Brazil, and FAPEMIG – Fundação de Amparo à Pesquisa do Estado de Minas Gerais, Belo Horizonte, Brazil. These research agencies had no influence in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.

PII: S0954-6111(09)00374-6

doi: 10.1016/j.rmed.2009.11.010

Respiratory Medicine
Volume 104, Issue 4 , Pages 606-611 , April 2010

Article Tools